Xyzagen was founded as an idea and extension of what our founder had been involved with all along: early discovery pharmacology, bioanalysis, and pharmacokinetics to regulated GLP toxicokinetics/bioanalysis and clinical pharmacology; from bench to bedside. We’re not focused on high-throughput screening, deep AI, or other marketing gimmicks. Our secret sauce is experience and knowing how to design nonclinical and clinical pharmacology solutions that provide both regulatory rigor and the scientific knowledge needed to move programs forward to the next value inflection point. After leaving Big Pharma, our founder built bioanalytical and pharmacokinetic capacity at two early-stage biotech companies in the RTP area. This integration of early bioanalysis and in vivo pharmacokinetics helped move discovery programs forward.

We believe that running a rodent or nonrodent PK study should be straightforward—but in reality, it pulls together four critical disciplines: chemistry and formulation development, animal husbandry and sample collection, bioanalytical sciences, and pharmacokinetics. Each of these disciplines is essential to understanding the pharmacokinetics and pharmacology of a drug, and any one component done poorly can compromise interpretation of the exposure–response relationship. These studies are critical to drug development and to the design of toxicology and clinical pharmacology programs, and they should not be discounted. Yet for large CROs, these studies are often treated as nonessential since there’s more revenue to be made in a 28-day toxicology study than in a 2-day pharmacokinetic study.